Medicinal Chemistry

Charnwood Molecular can offer medicinal chemistry support to the pharmaceutical and biotechnology industries. Our medicinal chemists have experience of working in various therapeutic areas including urology and pain, oncology, obesity, immunology, respiratory, inflammatory and the treatment of cardiovascular diseases.

Charnwood Molecular can provide high-value expertise and input into clients’ medicinal chemistry projects through its carefully-selected partnership arrangements. We are proud to work with other leading companies based alongside us at BioCity to offer an “in-house” integrated discovery and development service.

Collaborations with these leading companies enable us to deliver timely and effective solutions to our clients’ projects in a seamless manner. All of our partner companies employ industry-leading scientists with many years “big pharma” experience (ePfizer, Astrazeneca) – you can read more about the services provided by our Partners using the link shown above.

Our services include:

Lead Discovery:

• Design and synthesis of singletons and small focused libraries
• Confirmation that a true structure-activity relationship (SAR) exists within a chemical series
• Establish a clear direction for increasing potency and selectivity whilst reducing any metabolic liability

Lead Optimisation and Development:

• Design and synthesis of singletons and small focused compound libraries from a lead compound
• Confirmation that a true structure-activity relationship (SAR) exists within a chemical series
• Establish a clear direction for increasing potency and selectivity whilst reducing any metabolic liability
• Enhance compound properties such as novelty, diversity, drug-likeness, patentability, physical properties and scalability
• In-vitro profiling including potency and selectivity
•In-vivo profiling including oral bioavailability in animals and mode of action
• Preclinical ADME including drug metabolism and absorption, toxicity and
• PK/PD studies through our selected partners
• Screening options – Integrated approach via our selected partners
• Route development and scale-up for early toxicology studies and patent exemplification
• Design and synthesis of pro-drugs, putative metabolites process impurities